Complement Factor H ELISA Kit
Complement factor H (CFH) is a major soluble regulator of the complement system and plays an essential role in maintaining complement homeostasis and protecting host tissues from excessive complement activation. It is a glycoprotein with a molecular mass of approximately 150 kDa and a circulating concentration of approximately 400–800 µg/mL. CFH consists of 20 short consensus repeat (SCR) domains, each containing approximately 60 amino acids, which provide multiple binding sites for complement components and host-cell surface structures. Its primary regulatory function is to control the alternative pathway by binding to C3b, accelerating the decay of the C3 convertase (C3bBb), and acting as a cofactor for factor I-mediated cleavage and inactivation of C3b. The N-terminal SCR domains mediate complement regulation in the fluid phase, while the C-terminal region, particularly SCR domains 19–20, recognizes C3b and polyanionic markers on host cell surfaces. This enables CFH to distinguish host tissues from foreign surfaces and limit inappropriate complement activation. CFH also interacts with other molecules, including C-reactive protein (CRP), contributing to the regulation of inflammatory responses.
In research settings, CFH is studied for its central role in alternative pathway regulation, complement-mediated inflammation, and protection against tissue injury. Its ability to control C3 convertase activity and promote C3b inactivation makes it an important component of investigations into complement dysregulation and immune-mediated tissue damage. Genetic variations in the CFH gene can alter protein expression, binding properties, or regulatory function, potentially disrupting complement control and increasing susceptibility to complement-associated disorders. Particular attention has been given to genetic variants affecting the C-terminal recognition domains, which may impair CFH binding to host cell surfaces and reduce protection against local complement activation.
In clinical research, CFH has been extensively investigated in relation to renal and ocular disorders associated with complement dysregulation. Variants or functional abnormalities in CFH are strongly associated with atypical hemolytic uremic syndrome (aHUS), a complement-mediated thrombotic microangiopathy, and have also been implicated in certain forms of membranoproliferative glomerulonephritis (MPGN). Genetic variants in CFH are also among the major inherited risk factors for age-related macular degeneration (AMD), reflecting the importance of alternative pathway regulation in retinal health. Measurement of CFH concentrations may help researchers investigate complement regulation and identify quantitative deficiencies; however, normal concentrations do not necessarily indicate normal protein function, as genetic variants or acquired autoantibodies can impair its regulatory activity. Therefore, assessment of CFH concentration alongside genetic and functional complement analyses can provide a more comprehensive understanding of complement-associated disease mechanisms.
This Complement Factor H ELISA Kit is manufactured in Netherlands by Hycult Biotech.
| Size | |
| Sensitivity | 3.9 ng/mL |
| Dynamic Range | 3.9 – 250 ng/mL |
| Incubation Time | 2 hours 30 minutes |
| Sample Type | Serum, Plasma, Urine |
| Storage | 2-8°C |
| Alternative Names | CFH, Factor H, Beta-1H globulin |







